Worldwide, 41 billion people over the age of 25 years suffer from high blood pressure, defined as systolic pressure ⩾ 140 mm Hg and/or diastolic ⩾ 90 mm Hg, making hypertension the single most important cause of early mortality. 1 Hypertension claims more lives annually than obesity, prediabetes and high cholesterol combined and was responsible for~9.4 million deaths (13% of total global mortality) in 2010. 2 Although trends in awareness, treatment and control of hypertension have significantly improved, particularly in the United States and Western Europe, reducing its population prevalence continues to be a major global health crisis. From 2001 to 2009, the number of Americans with hypertension actually increased, with current estimates indicating~78 million people are affected, 3 accounting for 1000 deaths each day. 4 Yet, in low-and middle-income countries, hypertension has emerged as an even more serious public health problem. Indeed, although the number of people with hypertension is highest in these regions compared with highincome countries, 1 many more people are undiagnosed and poorly treated, accelerating their burden of atherothrombotic disease. 5 Future projections are discouraging. Analysis from the World Economic Forum and the Harvard School of Public Health in collaboration with the World Health Organization indicates that low-and middle-income countries will suffer an economic loss of nearly $4 trillion in the next decade solely attributed to cardiovascular diseases (CVD), most from the widespread clinical consequences of raised blood pressure. 6 In the US alone, the prevalence of hypertension is expected to increase by 27 million people in the next 15 years, placing an inconceivable annual financial toll of $400 billion in hypertension-related medical costs. 7 What is more concerning is that we have come to realize that the adverse vascular impacts of elevated blood pressure commence and progress well before someone becomes hypertensive (o140/90 mm Hg). This notion was first put forth by Robinson and Brucer in late 1930s following a series of studies showing a progressive rise of early death from CVD in persons with blood pressure between 120 and 140 mm Hg. 8 As a result of these important findings, Robinson and Brucer introduced the term 'prehypertension' to indicate an increased mortality risk zone of raised blood pressure. Seventy-five years later, we have amassed a large body of impressive data from many epidemiological and prospective cohort studies that clearly show a considerable vascular risk in the prehypertensive blood pressure range, 9 now defined as untreated systolic pressure 120-139 mm Hg and/or diastolic pressure 80-89 mm Hg. 10 Chronic elevations in blood pressure in the prehypertensive range are atherogenic, contributing to widespread vascular and structural damage to all organs and tissues, particularly the heart, brain and kidneys. Increased carotid intima-media thickness, coronary artery calcification, abnormal left ventricular morphology and diastolic dysfunction, reduced large-artery elasticity, aortic stiffening and vascular endothelial dysfunction are some of the major abnormalities that commence and progress in the prehypertensive state. The population burden of disease attributable to prehypertension, which affects~80 million Americans, is responsible for half of all deaths from ischemic heart disease and stroke worldwide. 5 Most of the mortality risk occurs in those with systolic pressure o140 mm Hg. Moreover, each 20/10 mm Hg increase in pressure above 115/75 mm Hg doubles the risk of death from atherothrombotic vascular disease, even before the onset of overt hypertension. 11 The cardiovascular health consequences of prehypertension afflict men, women and children of all ethnicities who are independent of traditional risk factors, and invariably affect people across all socioeconomic and education levels. 9 Despite this breadth of evidence, the precise mechanisms underlying the considerable CVD risks associated with prehypertension elude us. Recently, however, new scientific findings provide important evidence showing that prehypertension diminishes the inherent properties of the vascular endothelium to protect against thrombotic clots.
In this issue of the Journal of Human Hypertension, Diehl et al.
12
conducted an excellent study to determine the impact of prehypertension on endothelial fibrinolytic capacity in 42 middle-aged and older men (16 normotensive, 16 prehypertensive and 10 hypertensive). Fibrinolysis, a critical function of the endothelium, is an enzyme-regulated process that breaks up fibrin, the protein network of an intravascular thrombus. Impaired fibrinolysis is a key event accelerating atherogenesis; indeed, it leads to uncontrolled fibrin deposition, propagating the progression to an occlusive thrombus. Fibrinolytic capacity can be effectively determined by measuring acute endothelial release of tissue-type plasminogen activator (t-PA), a serine protease produced in endothelial cells that serves as the primary activator of the fibrinolytic system. In the presence of an intravascular thrombus, t-PA converts the proenzyme plasminogen to its active enzyme plasmin that breaks down fibrin thereby lysing the clot. Importantly, to initiate spontaneous thrombolysis, acute release of t-PA is absolutely critical because it rapidly increases its local concentration promoting faster and more complete resolution of a clot and preventing it from blocking blood flow. Indeed, the capacity of the endothelium to release t-PA represents in vivo fibrinolytic potential and is a well-established independent predictor of acute thrombotic events. 13 Although it is clear from previous data indicating that prehypertension is characterized by greater thrombotic tendency (that is, increased plasma levels of fibrinogen, thrombomodulin and plasminogen activator inhibitor-1 antigen), 14 until now no study investigated its effects on endothelial fibrinolytic capacity. Using a cross-sectional approach, Diehl et al. employed a well-established intra-arterial fibrinolytic protocol coupled with forearm venous occlusion plethysmography to assess acute endothelial release of t-PA in response to bradykinin. One main finding of the study was a considerably lower (~35%) release of t-PA in prehypertensive men (220 ± 24 ng per 100 ml tissue) compared with normotensive men (341 ± 34 ng per 100 ml tissue). This degree of impairment with prehypertension is consistent with other major CVD risk factors including aging, obesity, metabolic syndrome and even clinical hypertension. These novel data provide experimental support, suggesting that a primary mechanism contributing to the increased risk of CVD with prehypertension is of poor capacity to eliminate microvascular fibrin clots, which may propagate the progression to thrombosis and ischemic events. Their findings confirm and extend work done by Hrafnkelsdottir et al. 15 who initially demonstrated impaired t-PA release with hypertension, by showing that the onset of endothelial fibrinolytic dysfunction with elevated blood pressure manifests in the prehypertensive state. Certainly, Diehl et al. showed that the level of impairment in t-PA release with prehypertension was similar in severity to hypertensive subjects (213 ± 47 ng per 100 ml tissue). This is an important clinical finding as it reinforces the fact that endothelium is particularly sensitive to the deleterious effects of mild increases in blood pressure well before hypertension. Furthermore, as mentioned by the authors, it emphasizes the critical need to intervene early in prehypertension by encouraging lifestyle choices to lower blood pressure to optimal levels (that is, below 120/80 mm Hg) and thwart further endothelial dysfunction and vascular disease.
An interesting aspect of the study conducted by Diehl et al. was that all subjects, particular the normotensive and prehypertensive men, were well matched for age, body composition, fitness, and plasma lipids, lipoproteins and glucose. In addition, and perhaps even more important, all subjects were non-medicated, free of traditional risk factors (other than elevated blood pressure), and did not have CVD and metabolic disease. Although it could be argued that the study sample does not represent the typical clinical characteristics of the general population (most people with prehypertension also have additional CVD risk factors), this experimental approach was necessary to isolate the independent effects of prehypertension on t-PA release. As pointed out by the authors, it is not possible to eliminate all variables that might influence outcomes in cross-sectional studies. Nevertheless, given the careful subject screening and experimental expertise of the investigative team, it is likely that the observed impairment in endothelial t-PA release with prehypertension was a primary effect of elevated blood pressure and not owing to other factors, particularly the presence of additional risk factors that have been shown to reduce t-PA release.
The important work by Diehl et al. has brought to the forefront many pressing unanswered questions regarding the adverse endothelial fibrinolytic impacts of prehypertension. What is the underlying endothelial pathology contributing to impaired release of t-PA in the prehypertensive blood pressure range? Do differences in sex, age or ethnicity impair fibrinolytic capacity to a similar degree in prehypertensive individuals or is it worse in different groups of people? Do recommended lifestyle strategies to lower blood pressure (that is, DASH diet, weight loss and regular exercise training) restore endothelial health in prehypertensive persons?
The endothelial consequences of prehypertension are considerable and cannot be overlooked. Along with the present findings of poor endothelial fibrinolytic capacity, prehypertension is also characterized by reduced nitric oxide-mediated endotheliumdependent vasodilation, increased endothelin-1 vasoconstriction, increased arterial stiffness and reduced endothelial repair. The array of vascular abnormalities occurs at blood pressure levels that were once considered healthy. Indeed, they are central to the accelerated risk of CVD in prehypertensive persons. Now is the time to move towards a more comprehensive approach to prevent and treat this growing global health concern.
